Philip Gotwals, Ph.D.

Philip Gotwals became a Partner at Red Sky Partners in 2023 and is building a practice serving company management and investors in the biotechnology and pharmaceutical industry leveraging his extensive executive experience in corporate strategy, business development, research and product development.

Phil was most recently the Global Head, Business Development and Licensing, at Novartis Institutes for BioMedical Research (NIBR) where he oversaw business development efforts for all disease areas and technology platforms. Under Phil’s leadership, NIBR BD&L executed over 50 major strategic transactions including license and collaborations, acquisitions, asset sales, and new company creations. Previously, Phil held leadership positions in the Oncology Disease Area where he was instrumental in building NIBR’s immuno-oncology strategic research area including the engineered CAR-T platform. Prior to Novartis, Phil was on the management team of Altus Pharmaceuticals, and spent 12 years at Biogen in research, development, and program management. He has nearly 30 years of experience in discovery research; product development to NDA; program and portfolio management; therapeutic area strategy; and corporate/business transactions. Phil serves on the board of Capricor Therapeutics, Inc.

Phil holds a Ph.D. in genetics from the University of California at Berkeley; completed postdoctoral research at the Massachusetts Institute of Technology; and business training at Harvard Business School.